Two-round allele specific-polymerase chain reaction: A simple and highly sensitive method for JAK2V617F mutation detection

被引:15
|
作者
Kannim, Supattra [2 ]
Thongnoppakhun, Wanna [3 ]
Auewarakul, Chirayu U. [1 ]
机构
[1] Mahidol Univ, Siriraj Hosp, Fac Med, Div Hematol,Dept Med, Bangkok 10700, Thailand
[2] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Immunol, Bangkok 10700, Thailand
[3] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Res & Dev, Bangkok 10700, Thailand
关键词
Myeloproliferative disorders; JAK2 mutation detection; AS-PCR; DHPLC; RFLP; Sequencing; JAK2 V617F MUTATION; CHRONIC MYELOPROLIFERATIVE DISORDERS; STEM-CELL TRANSPLANTATION; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; MYELOID METAPLASIA; MYELOFIBROSIS; SYSTEM; MODEL;
D O I
10.1016/j.cca.2008.12.010
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Philadelphia chromosome (Ph-1)-negative myeloproliferative disorders (MPD) are hematopoietic stem cell disorders characterized by extensive proliferation of myeloid blood cells. JAK2V617F has recently been identified in the majority of Ph-1-negative MPD and becomes an essential diagnostic marker. Methods: To screen for JAK2V617F, a two-round allele specific-polymerase chain reaction (AS-PCR) was developed and compared to PCR-restriction fragment length polymorphism (PCR-RFLP), denaturing high performance liquid chromatography (DHPLC), and DNA sequencing. A primary AS-PCR was performed followed by a secondary AS-PCR, which was an amplification of the primary AS-PCR products using the same set of primers under alternative conditions. Results: By primary AS-PCR, a strong mutant-DNA band was seen in the DNA mixture containing as low as 2.5% of mutant allele. An ambiguous band was seen in 1% dilution while being totally absent in 0.1% dilution. After secondary AS-PCR, a mutant DNA band was clearly detected at 0.01% dilution. The detection sensitivity of PCR-RFLP and DHPLC was 2.5% while sequencing analysis was unable to detect below 5% dilution. Conclusion: Two-round AS-PCR is simple and inexpensive, making it a suitable method for JAK2V617F mutation screening. Moreover, monitoring of minimal residual disease after specific treatment of Ph-1-negative MPD patients should be feasible with this highly sensitive method. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:148 / 151
页数:4
相关论文
共 50 条
  • [41] JAK2V617F detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis
    Strati, Paolo
    Benton, Christopher B.
    Manshouri, Taghi
    Zhang, Ying
    Bove, Joseph E.
    Sanchez-Petitto, Gabriela
    Verstovsek, Srdan
    LEUKEMIA RESEARCH, 2017, 63 : 53 - 55
  • [42] Detection of the JAK2V617F mutation in patients with slightly elevated platelets or hemoglobin without a secondary cause
    Leonie Strobbe
    Peter Lestrade
    Mirjam H. A. Hermans
    Rob Fijnheer
    Annals of Hematology, 2007, 86 : 801 - 803
  • [43] Design and Application of a Novel PNA Probe for the Detection At Single Cell Level of JAK2V617F Mutation
    Cilloni, Daniela
    Rosso, Valentina
    Torti, Davide
    Carnuccio, Francesca
    Serra, Anna
    Nicoli, Paolo
    Gaidano, Valentina
    Campia, Valentina
    Signorino, Elisabetta
    Calabrese, Chiara
    Carturan, Sonia
    Favole, Alessandra
    Saglio, Giuseppe
    Frassoni, Francesco
    Bracco, Enrico
    BLOOD, 2012, 120 (21)
  • [44] Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis
    Alchalby, Haefaa
    Badbaran, Anita
    Zabelina, Tatjana
    Kobbe, Guido
    Hahn, Joachim
    Wolff, Daniel
    Bornhaeuser, Martin
    Thiede, Christian
    Baurmann, Herrad
    Bethge, Wolfgang
    Hildebrandt, York
    Bacher, Ulrike
    Fehse, Boris
    Zander, Axel R.
    Kroeger, Nicolaus
    BLOOD, 2010, 116 (18) : 3572 - 3581
  • [45] A longitudinal study of the JAK2V617F mutation in myelofibrosis with myeloid metaplasia: analysis at two time points
    Mesa, Ruben A.
    Powell, Heather
    Lasho, Terra
    DeWald, Goron W.
    McClure, Rebecca
    Tefferi, Ayalew
    HAEMATOLOGICA, 2006, 91 (03) : 415 - 416
  • [46] The presence of the JAK2V617F mutation in primary myelofibrosis and its allele burden in polycythemia vera predict chemosensitivity to hydroxyurea
    Sirhan, Shireen
    Huang, Jocelin
    Li, Chin-Yang
    Tefferi, Ayalew
    BLOOD, 2007, 110 (11) : 1036A - 1036A
  • [47] THE JAK2V617F MUTATION STATUS AND ALLELE BURDEN IN THAI PATIENTS WITH POLYCYTHEMIA VERA (PV) AND ESSENTIAL THROMBOCYTHEMIA (ET)
    Singdong, Roongrudee
    Siriboonpiputtana, Teerapong
    Kongruang, Adcharee
    Limsuwanachot, Nittaya
    Chareonsirisuthigul, Takol
    Chuncharunee, Suporn
    Sirirat, Tanasan
    Rerkamnuaychoke, Budsaba
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 : 98 - 98
  • [48] Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms
    Hu, Linhui
    Pu, Lianfang
    Ding, Yangyang
    Li, Manman
    Cabanero, Michael
    Xie, Jingxin
    Zhou, Dejun
    Yang, Dongdong
    Zhang, Cui
    Wang, Huiping
    Zhai, Zhimin
    Ru, Xiang
    Li, Jingrong
    Xiong, Shudao
    HEMATOLOGY, 2017, 22 (06) : 354 - 360
  • [49] Standardization of real-time quantitative polymerase chain reaction for detection of the JAK2V617F mutation in BCR-ABL1 negative myeloproliferative neoplasms: A Tertiary Care Centre experience
    Chatterjee, Tathagat
    Dewan, Khushboo
    Srivastava, Ritu
    CLINICAL CANCER INVESTIGATION JOURNAL, 2015, 4 (06): : 703 - 706
  • [50] Association of polycythemia vera with positive JAK2V617F mutation and myasthenia gravis: A report of two cases
    Sasi, Sreethish
    Yassin, Mohamed A.
    Kamran, Sadat
    Mnatsakanyan, Vazgen
    CLINICAL CASE REPORTS, 2021, 9 (01): : 531 - 534